News

BioArctic AB's (publ) partner Eisai announced that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab, an investigational…
Read More...

CytomX Therapeutics, Inc. announced that it achieved a clinical candidate milestone under its TCB agreement with Astellas. The clinical candidate is the first Probody TCB molecule to…
Read More...

The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which is being investigated as a potential…
Read More...

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic…
Read More...

Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, announced that it has raised additional funding, with Sunstone Life Science…
Read More...

Sandoz, the global leader in off-patent (generic and biosimilar) medicines, has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine…
Read More...

Lupin Digital Health, a wholly-owned subsidiary of global pharma major Lupin Limited, announced the launch of its digital therapeutics solution, LYFE. LYFE is India’s only…
Read More...

As part of a global, multiyear agreement, Thermo Fisher Scientific today announced it is working with AstraZeneca to develop a solid tissue and blood-based companion diagnostic (CDx)…
Read More...

Alvotech and Bioventure, a wholly owned subsidiary of GlobalOne Healthcare Holding LLC (“GHH”), the healthcare division of Yas Holding LLC, today announced that the Saudi Food &…
Read More...

Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces that its partner AFT…
Read More...

Takeda announced that it has entered into an exclusive licensing agreement with HUTCHMED (China) Limited (Nasdaq/AIM: HCM, HKEX: 13) and its subsidiary HUTCHMED Limited, for the further…
Read More...

BioCryst Pharmaceuticals, Inc. announced the company has entered into a collaboration with Swixx BioPharma AG to commercialize ORLADEYO (berotralstat) in Central and Eastern Europe…
Read More...

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of…
Read More...

Blueprint Medicines Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental new drug application for AYVAKIT (avapritinib) for the…
Read More...

Evaxion Biotech A/S announced that the U.S. Food and Drug Administration (“FDA”) has granted fast track designation for the Company’s personalized cancer therapy, EVX-01, in combination…
Read More...

Exegenesis Bio, a rapidly growing global gene therapy company is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND)…
Read More...

Genexine, a publicly traded, clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs,…
Read More...

Disc Medicine, Inc. announced that is has entered into an agreement with Mabwell Therapeutics to obtain an exclusive license to a portfolio of monoclonal antibodies targeting TMPRSS6…
Read More...

Oerth’s unique PROTAC protein degradation technology is expected to be a new, game-changing generation of more sustainable crop protection products / The agreement recommits to the…
Read More...

Evaxion Biotech A/S announced that the U.S. Food and Drug Administration (“FDA”) has granted fast track designation for the Company’s personalized cancer therapy, EVX-01, in combination…
Read More...